Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



ELI LILLY AND COMPANY Hits Price Target Forecast on QuantWave Platform, Delivering 22.87% Profit

November 08, 2022
ELI LILLY AND COMPANY, a pharmaceutical giant, has successfully reached the price target forecast set on the QuantWave platform, resulting in a lucrative profit of 22.87%. The forecast, issued on 2022-05-16, indicated a long position with a target price of 358.37 $. This target was achieved on 2022-11-08, surpassing the initial price of 291.66 $.

The positive price movement of ELI LILLY AND COMPANY can be attributed to various factors, including robust financial performance, successful product launches, and a favorable regulatory environment. Additionally, increased demand for healthcare products and services amid the ongoing global health crisis has contributed to the stock's upward momentum.

QuantWave's accurate forecast for ELI LILLY AND COMPANY highlights the platform's effectiveness in providing valuable insights for investors seeking to capitalize on market opportunities. By leveraging advanced algorithms and data analytics, QuantWave enables users to make informed trading decisions and maximize their returns.

QuantWave is a leading automated forecasting platform that offers predictions for a wide range of stocks, presenting potential profit opportunities for investors. For a more in-depth understanding of QuantWave's investment approach, individuals are encouraged to explore the educational resources provided by QuantSchool. QuantSchool offers a comprehensive professional investment framework that elucidates the key principles for generating consistent income using the QuantWave forecasting system.
If you want to leave a comment, then you need Login or Register





Other data for LLY

Related data

LLYMarch 22, 2025Eli Lilly and Company LLY: Leading the Way in Pharmaceutical Innovation  ~2 min.

Eli Lilly and Company (LLY) continues to make waves in the pharmaceutical industry with its innovative and groundbreaking therapies....

LLYMarch 19, 2025Eli Lilly and Company LLY Surges After Breakthrough BRAVE-AA-PEDS Study Results  ~2 min.

Eli Lilly and Company (LLY) has recently made a significant breakthrough in its BRAVE-AA-PEDS study, resulting in a surge of investor attention and market gains....

LLYMarch 18, 2025Eli Lilly and Company: A Promising Investment in the Pharma Industry  ~1 min.

Eli Lilly and Company (LLY) has been making waves in the pharmaceutical industry with its innovative products and strong performance....

LLYMarch 17, 2025Eli Lilly and Company's Groundbreaking Discovery Revolutionizes Pharma Industry  ~2 min.

Eli Lilly and Company, a renowned pharmaceutical giant, has recently made a groundbreaking discovery that is set to revolutionize the entire industry....

LLYMarch 16, 2025Is Eli Lilly and Company LLY Set to Revolutionize the Pharma Industry?  ~2 min.

Eli Lilly and Company (LLY) has been making headlines recently with its groundbreaking research and innovative products....

LLYMarch 14, 2025Eli Lilly and Company Reports Promising Results in Hair Regrowth Study  ~1 min.

Eli Lilly and Company (LLY) recently announced the positive outcome of their Phase 3 clinical trial for baricitinib, a drug aimed at treating severe alopecia areata in adolescents....

LLYFebruary 28, 2025Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding 50 billion  ~1 min.

Eli Lilly and Company (LLY) is set to significantly increase its manufacturing investment in the United States, surpassing a staggering 50 billion since 2020....

LLYFebruary 27, 2025Eli Lilly and Company Acquires Organovos FXR Program in IBD Treatment Development  ~1 min.

Eli Lilly and Company has recently made headlines with its acquisition of Organovos FXR Program, a significant step towards advancing treatment options for Inflammatory Bowel Disease (IBD)....

LLYFebruary 26, 2025ELI LILLY AND COMPANY Launches Additional Zepbound Vial Doses and Offers New Savings  ~2 min.

ELI LILLY AND COMPANY has recently announced the launch of additional Zepbound vial doses, as well as new savings for self-pay patients....

LLYFebruary 25, 2025Major Stock Movement: Lilly to participate in TD Cowens 45th Annual Health Care Conference  ~2 min.

Eli Lilly and Company (LLY) has recently caught the attention of investors as it prepares to participate in the TD Cowens 45th Annual Health Care Conference....

REGNApril 8, 2025REGENERON PHARMACEUTICALS, INC. Stock Hits Price Target with 20% Profit: QuantWave Analysis  ~1 min.

In a recent success for QuantWave's forecasting platform, the stock of REGENERON PHARMACEUTICALS, INC. has hit its price target with a 20% profit margin....

REGNAugust 13, 2024REGENERON PHARMACEUTICALS, INC. Hits Price Target Forecast with Profit of 14.62%  ~1 min.

REGENERON PHARMACEUTICALS, INC. has successfully achieved the price target forecast as predicted by QuantWave's automated forecasting platform....

ABTFebruary 21, 2025ABBOTT LABORATORIES Stock Hits Price Target with 16.11% Profit: QuantWave Forecast Success  ~2 min.

On December 2, 2024, QuantWave, the automated forecasting platform, issued a long signal for ABBOTT LABORATORIES stock when it was trading at 115.66 $....

UNHJuly 16, 2024UNITEDHEALTH GROUP INCORPORATED Stock Hits QuantWave's Price Target with 8.74% Profit  ~2 min.

UNITEDHEALTH GROUP INCORPORATED (UNH) stock has successfully reached QuantWave's price target of 538.7 $ on July 16, 2024, yielding a profit of 8.74% from the forecast signal date of October 4, 2023....

BIIBOctober 31, 2024Biogen Inc. Hits Price Target Forecast with a Profit of 17.88%  ~2 min.

Biogen Inc. has successfully reached the price target forecasted by QuantWave on October 31, 2024. The forecast signal date was July 30, 2024, with a price of 211.89 $....